Somatostatina e/o Octreotide (analogo della somatostatina)

E’ un polipeptide (sostanza composta da amminoacidi) di 14 amminoacidi, che ha la proprietà specifica di inibire il principale fattore di crescita, il GH, che ha un ruolo fondamentale nell’insorgenza e proliferazione neoplastica. Svolge attività inibente anche su molti altri fattori di crescita che in misura significativa concorrono a determinare e diffondere la patologia neoplastica, quali prolattina, IGF, TGF alfa e beta, PDGF, EGF, VEGF. Numerosi analoghi di sintesi della somatostatina sono stati studiati e impiegati con successo in varie neoplasie. Fino dal 1988 negli USA la FDA ha approvato e registrato l’uso della somatostatina in diverse varietà tumorali. Attualmente un numero crescente di pubblicazioni sta confermando le proprietà antitumorali di questa sostanza in tutte le varietà neoplastiche con meccanismi d’azione sia diretti su recettori cellulari per la somatostatina, individuati nella cellula tumorale, che indiretti attraverso l’inibizione di quei fattori di crescita cui ormai è universalmente riconosciuto un ruolo primario nei tumori. Meccanismi d’azione sono antiproliferativo (inibisce la riproduzione di popolazioni cellulari neoplastiche), pro-apoptotico (induce una morte programmata delle cellule tumorali), antimetastatico (non consente la diffusione a distanza delle localizzazioni neoplastiche primitive. In queste azioni la somatostatina è sinergica e notevolmente potenziata dagli altri componenti dell’MDB, quali retinoidi, melatonina ecc.

Documenti scientifici associati:
 

Solo ricerca in vitro (organi isolati, tessuti, cellule o sistemi biochimici - definizione del libro d'oro IUPAC)

• 1977 Aug: Somatostatin-immunoreactive Cells in Medullary Carcinoma of the Thyroid;
• 1984 Apr: Inhibition by somatostatin of the proliferation of T-lymphocytes and Molt-4 lymphoblasts;
• 1985 Jan: Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line;
• 1985 Jun: The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients;
• 1986 Nov: Duodenal gangliocytic paragangliomas: a study of 10 cases with immunocytochemical neuroendocrine markers;
• 1987 Jan: Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin;
• 1987 Mar: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells;
• 1987 Nov: Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system;
• 1987 Dec: Identification of lymphoid cell lines bearing receptors for somatostatin;
• 1988 Feb: Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin;
• 1988 Jun: Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines;
• 1989 ???: Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer;
• 1989 Mar: Biochemical evidence for somatostatin receptors in murine neuroblastoma clone N1E-115;
• 1989 Mar: Correlative study on neuro-endocrine differentiation and presence of somatostatin receptors in breast carcinomas;
• 1989 Mar: Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase;
• 1989 Mar: Somatostatin in medullary thyroid cancer. In vitro and in vivo studies;
• 1989 Apr: Insulin-like growth factor-I action on growth hormone secretion and messenger ribonucleic acid levels: interaction with somatostatin;
• 1989 May: Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin;
• 1989 Sep: The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer;
• 1990 Mar: Evaluation of receptors for somatostatin in various tumors using different analogs;
• 1990 May: Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients;
• 1990 Sep: Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase;
• 1990 Sep: Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors;
• 1990 Dec: Somatostatin receptors on human lymphocytes and leukaemia cells;
• 1991 Feb: In vitro and in vivo detection of somatostatin receptors in human malignant tissues;
• 1991 May: Somatostatin receptors in differentiated ovarian tumors;
• 1991 Jul-Aug: Octapeptide analogues of somatostatin inhibit the clonal growth and vasoactive intestinal peptide-stimulated cyclic AMP formation in human small cell lung cancer cells;
• 1992 Feb: Molecular heterogeneity of somatostatin analogue BIM-23014C receptors in human breast carcinoma cells using the chemical cross-linking assay;
• 1992 Oct: Degradation of the neuropeptide somatostatin by cultivated neuronal and glial cells;
• 1992 Jan: Differential effects of LHRH and somatostatin analogs on human breast cancer;
• 1992 Feb: SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer;
• 1992 Apr: In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas;
• 1992 Jul: The binding of bombesin and somatostatin and their analogs to human colon cancers;
• 1992 Jul-Aug: Effect of somatostatin on adenylate cyclase activity in normal and neoplastic thyroid tissue;
• 1992 Sep: Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro;
• 1992 Sep: Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995);
• 1992 Oct: Neuroblastoma. Correlation of neuropeptide expression in tumor tissue with other prognostic factors;
• 1992 Nov: Somatostatin receptors in human renal cell carcinomas;
• 1992 Dec: Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase;
• 1993 Feb: Effect of somatostatin and its analogue on proliferation of human epidermoid carcinoma cells in vitro;
• 1993 Mar: A cross-linking assay allows the detection of receptors for the somatostatin analogue, lanreotide in human breast tumours;
• 1993 Mar: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1;
• 1993 Apr: Mechanisms of action of long-acting analogs of somatostatin;
• 1993 Jun: In vivo somatostatin receptor imaging in medullary thyroid carcinoma;
• 1993 Oct: In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue;
• 1994 ???: Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity;
• 1994 Jan: Identification, characterization, and biological activity of somatostatin receptors in human neuroblastoma cell lines;
• 1994 Jan: Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer;
• 1994 Jan: Somatostatin receptor expression in lung cancer;
• 1994 Feb: Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue;
• 1994 Mar: Somatostatin-receptor scintigraphy in primary breast cancer;
• 1994 Mar: Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2;
• 1994 Jul: Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization;
• 1994 Dec: Expression of somatostatin receptors in childhood neuroblastoma;
• 1995 Jan: Role of tumor-derived fibroblasts in the growth of primary cultures of human breast-cancer cells: effects of epidermal growth factor and the somatostatin analogue octreotide;
• 1995 Feb: Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms;
• 1995 May: Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103;
• 1995 Sep: Somatostatin receptors in human prostate and prostate cancer;
• 1996 Feb: Somatostatin-14 mainly binds the somatostatin receptor subtype 2 in human neuroblastoma tumors;
• 1996 Mar: Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin;
• 1996 Apr: Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification;
• 1996 Oct: A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity;
• 1996 Oct: Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction;
• 1996 Nov: A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines;
• 1997 Jan: Time-dependent influence of the somatostatin analogue octreotide on the proliferation of rat astrocytes and glioma cells;
• 1997 Feb: Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995);
• 1997 Feb: Somatostatin and growth hormone-releasing hormone in normal and tumoral human breast tissue: endogenous content, in vitro pulsatile release, and regulation;
• 1997 Feb: Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae;
• 1997 Mar: Analysis of somatostatin receptor subtype mRNA expression in human breast cancer;
• 1997 Mar: Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography;
• 1997 Jun: Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines;
• 1997 Sep: The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling;
• 1997 Oct: Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells;
• 1997 Dec: Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors;
• 1998 Mar: Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II;
• 1998 Apr: Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma;
• 1998 Apr: Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells;
• 1998 May: Expression of somatostatin receptor subtypes in human brain tumors;
• 1998 Jun: Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: a possible mechanism of antitumor action;
• 1998 Jul: Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma;
• 1998 Sep: Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies;
• 1998 Sep: Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses;
• 1999 Jan: Expression of somatostatin receptors in peritumoral veins of human tumors;
• 1999 Jan: Molecular analysis of the somatostatin receptor subtype 2 in human glioma cells;
• 1999 Feb: Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1;
• 1999 Mar: The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines;
• 1999 Apr: Somatostatin controls Kaposi’s sarcoma tumor growth through inhibition of angiogenesis;
• 1999 Jun: Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232;
• 1999 Aug: Biology of Somatostatin and Somatostatin Receptors in Breast Cancer;
• 1999 Aug: SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release;
• 1999 Sep: Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160;
• 1999 Oct: Somatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells;
• 2000 Jan: Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro;
• 2000 Feb: Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells;
• 2000 Feb: The somatostatin analogue peptide TT-232 induces apoptosis and chromosome breakage in cultured human lymphocytes;
• 2000 Mar: Expression of somatostatin type 2A receptor correlates with estrogen receptor in human breast carcinoma;
• 2000 Mar: Somatostatin receptor gene expression in neuroblastoma;
• 2000 Apr: Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro;
• 2000 May: Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A;
• 2000 May: Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography;
• 2000 Jun: Somatostatin analog SMS 201995 inhibits proliferation in human leukemia T-cell line: relevance of the adenylyl cyclase stimulation;
• 2000 Jun: Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo;
• 2000 Jul: High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers;
• 2000 Sep: Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone;
• 2000 Oct: Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers;
• 2000 Oct: Human ovarian cancers express somatostatin receptors;
• 2000 Oct: Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome;
• 2000 Oct: Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location;
• 2001 Jan: Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients;
• 2001 Jan: Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells;
• 2001 Feb: Immunohistochemical localization of somatostatin receptor type 2A in rat and human tissues;
• 2001 Feb: Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells;
• 2001 Apr: Somatostatin induces migration of acute myeloid leukemia cells via activation of somatostatin receptor subtype 2;
• 2001 May: Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice;
• 2001 May: Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid;
• 2001 May: Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells;
• 2001 May: Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt;
• 2001 Jul: Growing vascular endothelial cells express somatostatin subtype 2 receptors;
• 2001 Jul: Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3;
• 2001 Jul: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands;
• 2001 Jul: The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src;
• 2001 Aug: Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide;
• 2001 Oct: Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone;
• 2001 Oct: The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation;
• 2001 Nov: Antineoplastic mechanism of Octreotide action in human hepatoma;
• 2001 Nov: Physical and functional interactions between protein tyrosine phosphatase alpha, PI 3-kinase, and PKCdelta;
• 2001 Dec: Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy;
• 2002 Feb: Immunohistochemical detection of somatostatin receptors in human ovarian tumors;
• 2002 Feb: Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status;
• 2002 May-Jun: Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines;
• 2002 Jun: Comparison of somatostatin receptor expression in human gliomas and medulloblastomas;
• 2002 Jul: Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting;
• 2002 Jul: Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours;
• 2002 Oct: Cholangiocarcinoma cells express somatostatin receptor subtype 2 and respond to octreotide treatment;
• 2002 Oct: Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II;
• 2002 Oct: Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line;
• 2002 Nov: Somatostatin receptors in nasopharyngeal carcinoma;
• 2003 Feb: Conserved motifs in somatostatin, D2-dopamine, and alpha 2B-adrenergic receptors for inhibiting the Na-H exchanger, NHE1;
• 2003 Feb: Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers;
• 2003 Apr: Expression of somatostatin receptors in uveal melanomas;
• 2003 Apr: Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities;
• 2003 Jun: Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer;
• 2003 Jun: Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts;
• 2003 Aug: Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity;
• 2003 Oct: Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas;
• 2003 Dec: Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin;
• 2004 Jan: Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers;
• 2004 Mar: Oestrogen-mediated Regulation of Somatostatin Receptor Expression in Human Breast Cancer Cell Lines Assessed With 99mTc-depreotide;
• 2004 Apr: Antineoplastic effects of octreotide on human gallbladder cancer cells in vitro;
• 2004 Jun: Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue;
• 2004 Jul: Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas;
• 2004 Jul: The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation;
• 2004 Aug: Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis;
• 2004 Aug: Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by somatostatin receptor subtype 2;
• 2004 Aug: The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells;
• 2004 Oct: Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells;
• 2004 Oct: Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells;
• 2005 Jan: Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice;
• 2005 Jan: Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways;
• 2005 Jan-Feb: Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models;
• 2005 Mar: Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway;
• 2005 Apr: Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium;
• 2005 May: Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238;
• 2005 Jul: Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone;
• 2005 Jul: Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology;
• 2006 Feb: Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression;
• 2006 Mar: Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells;
• 2006 Mar: Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives;
• 2006 Mar: The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth;
• 2006 Apr: Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer;
• 2006 Sep-Oct: Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models;
• 2007 Jan: An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta;
• 2007 Jan: Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas;
• 2007 Feb: Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways;
• 2007 Feb: Somatostatin regulates hepatic growth hormone sensitivity by internalizing growth hormone receptors and by decreasing transcription of growth hormone receptor mRNAs;
• 2007 Jun: A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide;
• 2008 Jan: Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis;
• 2008 Feb: Somatostatin receptor in human hepatocellular carcinomas: biological, patient and tumor characteristics;
• 2008 Mar: Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues;
• 2008 Mar: Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR;
• 2008 May: Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas;
• 2008 Jun: Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study;
• 2008 Aug: The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data;
• 2008 Sep: Detection of somatostatin receptors in human osteosarcoma;
• 2008 Sep: Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation;
• 2008 Sep: Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2;
• 2008 Sep-Oct: Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin;
• 2008 Sep-Oct: Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes;
• 2008 Nov: Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer;
• 2009 Jan: Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro;
• 2009 Jan: Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation;
• 2009 Jan: Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways;
• 2009 Feb: Octreotide inhibits growth of colonic cancer SW480 cells by modulating the Wnt/β-catenin pathway;
• 2009 Feb: Somatostatin analogues inhibit cancer cell proliferation in an SSTR2-dependent manner via both cytostatic and cytotoxic pathways;
• 2009 Mar: Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies;
• 2009 Mar: Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells;
• 2009 Apr: Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas;
• 2009 May: Effects of non-cytotoxic drugs on the growth of multidrug-resistance human gastric carcinoma cell line;
• 2009 Jun: Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly;
• 2009 Jun: Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues;
• 2009 Jul: Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide;
• 2009 Jul: The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells;
• 2009 Jul-Aug: Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies;
• 2009 Oct: GHRH Antagonist Causes DNA Damage Leading to p21 Mediated Cell Cycle Arrest and Apoptosis in Human Colon Cancer Cells;
• 2009 Oct: Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer;
• 2009 Nov: Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy;
• 2009 Nov-Dec: Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation;
• 2009 Dec: Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin;
• 2009 Dec: hSSTR2 expression and octreotide treatment reverses multidrug resistance of BxPC-3 human pancreatic cancer cells;
• 2010 Feb: Regulation of prostate cancer cell proliferation by somatostatin receptor activation;
• 2010 Feb: The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways;
• 2010 Apr: Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents;
• 2010 Aug: Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog;
• 2010 Oct: Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model;
• 2010 Oct: Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer;
• 2010 Nov: Somatostatin analogue inhibits the mobility of prostate carcinoma cells: a new therapeutic method for advanced prostate carcinoma;
• 2010 Dec: Inhibitory effect of somatostatin Peptide analogues on DNA polymerase activity and human cancer cell proliferation;
• 2010 Dec: Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines;
• 2010 Dec: XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells;
• 2011 Jan: Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells;
• 2011 Mar: Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas;
• 2011 Mar: Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma;
• 2011 Apr: Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma;
• 2011 Apr: Differential temporal and spatial regulation of somatostatin receptor phosphorylation and dephosphorylation;
• 2011 Jun: Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer;
• 2011 Jun: Inhibitory effect of somatostatin analogue octreotide on the expression of p53 and Ras in human gastric cancer [Article in Chinese: Only the captions of images and tables are in English language];
• 2011 Sep: The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells;
• 2011 Nov-Dec: Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro;
• 2011 Dec: Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro;
• 2012 Jan: Somatostatin receptor subtype 2 A (SSTR2A) and HER2 expression in gastric adenocarcinoma;
• 2012 Jan: The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles;
• 2012 Apr: Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules;
• 2012 May: Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis;
• 2012 May: Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility;
• 2012 Jun: Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro;
• 2012 Jul: Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer;
• 2012 Jul-Sep: Somatostatin receptor expression in non-medullary thyroid carcinomas;
• 2012 Aug: Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung;
• 2012 Sep: Somatostatin subtype-2 receptor-targeted metal-based anticancer complexes;
• 2012 Oct: Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer;
• 2012 Oct: The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells;
• 2013 Feb: Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy;
• 2013 Feb: Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124];
• 2013 Mar: Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone;
• 2013 May: Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells;
• 2013 Jun: Somatostatin receptor expression in thyroid disease;
• 2013 Jul: Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies;
• 2013 Jul: Somatostatin receptors 3, 4 and 5 play important roles in gallbladder cancer;
• 2013 Aug: Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma;
• 2013 Sep: Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells;
• 2013 Sep: Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment;
• 2013 Nov: siRNA-targeted inhibition of growth hormone receptor in human colon cancer SW480 cells;
• 2013 Dec: Analysis of somatostatin receptors and somatostatin promoter methylation in human gastric cancer;
• 2014 Jan: Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer;
• 2014 Feb: Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth;
• 2014 Mar: Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer;
• 2014 Jun: Effects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activity;
• 2014 Aug: Expression of Somatostatin Type-2 and -4 Receptor and Correlation with Histological Type in Breast Cancer;
• 2014 Oct: Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models;
• 2014 Nov: Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy;
• 2014 Dec: Somatostatin Receptors in Bronchopulmonary Neuroendocrine Neoplasms: New diagnostic, prognostic and therapeutic markers;
• 2015 Feb: Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?;
• 2015 Feb: mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer;
• 2015 Feb: Promoter hypermethylation-related reduced somatostatin production promotes uncontrolled cell proliferation in colorectal cancer;
• 2015 Mar: Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma;
• 2015 Mar: Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas;
• 2015 May: Somatostatin Derivate (smsDX) Attenuates the TAM-Stimulated Proliferation, Migration and Invasion of Prostate Cancer via NF-κB Regulation;
• 2015 Jun: An immunohistochemical investigation of the expression of somatostatin receptor subtypes - should therapeutic trials be performed to determine the efficacy of somatostatin analogs in treating advanced thyroid malignances?;
• 2015 Jun: Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines;
• 2015 Jun: Somatostatin receptor 2 and 5 expressions in gastroenteropancreatic neuroendocrine tumors in Turkey;
• 2015 Oct: Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy;
• 2016 Mar: Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model;
• 2016 May: Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts;
• 2016 May: Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo;
• 2016 Jun: Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma;
• 2016 Aug: HIGHLY INCREASED 125I-JR11 ANTAGONIST BINDING IN VITRO REVEALS NOVEL INDICATIONS FOR SST2 TARGETING IN HUMAN CANCERS;
• 2016 Sep: The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients;
• 2016 Oct: Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis;
• 2016 Dec: Somatostatin signaling via SSTR1 contributes to the quiescence of colon cancer stem cells;
• 2017 Apr: Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography;
• 2017 Jul: The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer;
• 2017 Sep: Anti-SSTR2 peptide based targeted delivery of potent PLGA encapsulated 3,3'-diindolylmethane nanoparticles through blood brain barrier prevents glioma progression;
• 2017 Sep: Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas;
• 2017 Dec: Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer;
• 2017 Dec: Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma;
• 2018 Jan: Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer;
• 2018 Feb: HDAC inhibitors suppressed small cell lung cancer cell growth and enhanced the suppressive effects of receptor-targeting cytotoxins via upregulating somatostatin receptor II;
• 2018 May: A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone;
• 2018 Jun: An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma;
• 2018 Jun: Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma;
• 2018 Jul: New somatostatin-drug conjugates for effective targeting pancreatic cancer;
• 2018 Jul: Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1;
• 2018 Jul: Over-Expression of GH/GHR in Breast Cancer and Oncosuppressor Role of Somatostatin as a Physiological Inhibitor;
• 2018 Aug: Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer;
• 2018 Sep: Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer;
• 2018 Sep: Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome;
• 2018 Oct: Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A;
• 2018 Oct: Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer;
• 2018 Nov: Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers;
• 2018 Dec: Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas;
• 2019 Feb: Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma;
• 2019 Feb: Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells;
• 2019 Feb: Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models;
• 2019 Feb: Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells;
• 2019 Mar: Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin;
• 2019 Jun: Constant expression of somatostatin receptor 2a in minute pulmonary meningothelial-like nodules;
• 2019 Jul: Identification of aberrantly methylated differentially expressed genes in glioblastoma multiforme and their association with patient survival;
• 2019 Jul: Somatostatin receptor expression in parathyroid neoplasms;
• 2019 Aug: The Entrapment of Somatostatin in a Lipid Formulation: Retarded Release and Free Radical Reactivity (from Di Bella's Foundation);
• 2019 Sep: Effects of Somatostatin and Vitamin C on the Fatty Acid Profile of Breast Cancer Cell Membranes (from DiBella's Foundation);
• 2019 Sep: Effects of somatostatin, curcumin, and quercetin on the fatty acid profile of breast cancer cell membranes (from DiBella's Foundation);
• 2019 Nov: Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer;
• 2020 Feb: Knocking Out SST Gene of BGC823 Gastric Cancer Cell by CRISPR/Cas9 Enhances Migration, Invasion and Expression of SEMA5A and KLF2;
• 2020 Mar: Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours;
• 2020 Mar: Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas;
• 2020 Apr: Expression of potential therapeutic target SSTR2a in primary and metastatic non-keratinizing nasopharyngeal carcinoma;
• 2020 Jun: Investigation of somatostatin receptor profile of neuroendocrine carcinomas of the breast;
• 2020 Jul: Electrostatically bound lanreotide peptide - gold nanoparticle conjugates for enhanced uptake in SSTR2-positive cancer cells;
• 2020 Aug: Prognostic impact of somatostatin receptor expression in advanced bladder cancer;
• 2020 Oct: Fluorescent Nanoparticles Coated with a Somatostatin Analogue Target Blood Monocyte for Efficient Leukaemia Treatment;
• 2020 Nov: Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion;
• 2020 Nov: SSTR2a is constantly expressed in lymphoepithelioma-like carcinoma with squamous differentiation other than that with glandular differentiation;
• 2020 Dec: 177 Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer;
• 2020 Dec: Expression of Somatostatin Receptor Subtypes (SSTR-1-SSTR-5) in Pediatric Hematological and Oncological Disorders;
• 2021 Apr: Octreotide-Targeted Lcn2 siRNA PEGylated Liposomes as a Treatment for Metastatic Breast Cancer;
• 2021 Oct: Targeted paclitaxel-octreotide conjugates inhibited the growth of paclitaxel-resistant human non-small cell lung cancer A549 cells in vitro.

In Vivo (Solo animale)

• 1983 Feb: Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones;
• 1985 May: A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth;
• 1986 Dec: Somatostatin: a peptide with unexpected physiologic activities;
• 1987 Jun: Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin;
• 1987 Oct: Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer;
• 1988 ???: Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH;
• 1988 Feb: Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin;
• 1988 Aug: Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995);
• 1989 Mar: Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin;
• 1989 Nov: Effects of a somatostatin analogue (SMS 201-995) on the growth and development of hepatic tumour derived by intraportal injection of Walker cells in the rat;
• 1992 Feb: SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer;
• 1992 Mar: The effects of sandostatin (Octreotide, SMS 201-995) infusion on splanchnic and hepatic blood flow in an experimental model of hepatic metastases;
• 1992 Apr: In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas;
• 1992 Sep: Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro;
• 1992 Sep: Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995);
• 1993 Feb: Octreotide (SMS 201-995) inhibits the growth of colon peritoneal carcinomatosis in BDIX rats;
• 1993 Jun: Inhibitory effect of a somatostatin analogue (SMS 201-995) on the growth of androgen-dependent mouse mammary tumor (Shionogi carcinoma 115);
• 1994 Jan: Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer;
• 1994 Feb: Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue;
• 1994 Nov: Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice;
• 1996 Oct: A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity;
• 1997 Jan: Effects of octreotide on liver regeneration and tumour growth in the regenerating liver;
• 1997 Feb: Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995);
• 1997 Oct: Somatostatin in neuroblastoma and ganglioneuroma;
• 1998 Mar: Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II;
• 1998 Apr: Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma;
• 1998 Jun: Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: a possible mechanism of antitumor action;
• 1998 Sep: Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses;
• 1999 Apr: Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238;
• 1999 Apr: Somatostatin controls Kaposi’s sarcoma tumor growth through inhibition of angiogenesis;
• 1999 May: Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver;
• 1999 Jun: Epidermal growth factor receptor, somatostatin and bcl-2 in human pancreatic tumor xenografts. An immunohistochemical study;
• 1999 Aug: Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238;
• 1999 Aug: SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release;
• 1999 Aug-Sep: Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs;
• 1999 Sep: Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160;
• 2000 Feb: Effects of somatostatin analogs octreotide and lanreotide on the proliferation and apoptosis in colon 38 tumor: interaction with 5-fluorouracil;
• 2000 Mar: Somatostatin receptor gene expression in neuroblastoma;
• 2000 Jul: Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways;
• 2000 Sep: Effects of somatostatin and its analogues on tyrosine kinase activity in rodent tumors;
• 2000 Sep: Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone;
• 2000 Oct: Human ovarian cancers express somatostatin receptors;
• 2001 Jan: Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells;
• 2001 Feb: Immunohistochemical localization of somatostatin receptor type 2A in rat and human tissues;
• 2001 May: Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice;
• 2001 Jul: Growing vascular endothelial cells express somatostatin subtype 2 receptors;
• 2001 Aug: Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide;
• 2001 Oct: Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects;
• 2001 Oct: Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone;
• 2002 Feb: Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status;
• 2002 Apr: Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity;
• 2002 Oct: Cholangiocarcinoma cells express somatostatin receptor subtype 2 and respond to octreotide treatment;
• 2002 Oct: Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II;
• 2002 Dec: The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy;
• 2003 Feb: Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers;
• 2003 Apr: Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities;
• 2003 Jun: Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts;
• 2003 Oct: Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas;
• 2003 Dec: Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin;
• 2004 Jan: Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers;
• 2004 Feb: Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238;
• 2004 Aug: Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis;
• 2004 Aug: Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by somatostatin receptor subtype 2;
• 2004 Oct: Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells;
• 2005 Jan: Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice;
• 2005 Jan-Feb: Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models;
• 2005 May: Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238;
• 2005 Sep: Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1;
• 2006 Jan: The efficacy of octreotide in pancreatic and intestinal changes: radiation-induced enteritis in animals;
• 2006 Mar: The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth;
• 2006 Apr: Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations;
• 2006 Jun: Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins;
• 2006 Sep-Oct: Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models;
• 2007 Feb: Somatostatin regulates hepatic growth hormone sensitivity by internalizing growth hormone receptors and by decreasing transcription of growth hormone receptor mRNAs;
• 2007 Jun: A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide;
• 2008 Mar: Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues;
• 2008 Aug: Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways;
• 2008 Oct: Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice;
• 2008 Nov: Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer;
• 2009 Jan: Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways;
• 2009 Jun: A somatostatin analogue, octreotide, inhibits the occurrence of second primary tumors and lung metastasis after resection of hepatocellular carcinoma in mice;
• 2009 Jun: Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues;
• 2009 Jul: Effects of octreotide on necrosis of hepatocellular carcinoma xenografts in nude mice;
• 2009 Oct: GHRH Antagonist Causes DNA Damage Leading to p21 Mediated Cell Cycle Arrest and Apoptosis in Human Colon Cancer Cells;
• 2009 Oct: Impact of Octreotide and SOM-230 on liver metastasis and hepatic lipidperoxidation in ductal pancreatic adenocarcinoma in Syrian Hamster;
• 2010 Apr: Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents;
• 2010 Oct: Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model;
• 2011 Feb: Protective effects of melatonin and octreotide against radiation-induced intestinal injury;
• 2011 Mar: Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia;
• 2011 Sep: The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells;
• 2012 Jan: The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles;
• 2012 Oct: Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer;
• 2013 Feb: Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124];
• 2013 Mar: Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone;
• 2013 Nov: siRNA-targeted inhibition of growth hormone receptor in human colon cancer SW480 cells;
• 2014 Jan: Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer;
• 2014 Mar: Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma;
• 2014 Oct: Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models;
• 2015 May: Somatostatin Derivate (smsDX) Attenuates the TAM-Stimulated Proliferation, Migration and Invasion of Prostate Cancer via NF-κB Regulation;
• 2015 Dec: Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies;
• 2016 Mar: Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model;
• 2016 May: Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts;
• 2016 May: Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo;
• 2016 Sep: The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients;
• 2017 Apr: Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography;
• 2017 Jun: Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum;
• 2017 Jul: The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer;
• 2017 Sep: Anti-SSTR2 peptide based targeted delivery of potent PLGA encapsulated 3,3'-diindolylmethane nanoparticles through blood brain barrier prevents glioma progression;
• 2017 Dec: Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer;
• 2018 Jan: Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer;
• 2018 May: A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone;
• 2018 Jul: New somatostatin-drug conjugates for effective targeting pancreatic cancer;
• 2018 Jul: Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1;
• 2018 Oct: Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer;
• 2018 Oct: Strain-specific metastatic phenotypes in pheochromocytoma allograft mice;
• 2019 Feb: Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma;
• 2019 Feb: Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models;
• 2019 Nov: Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer;
• 2020 Mar: Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours;
• 2020 Mar: Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas;
• 2020 Oct: Fluorescent Nanoparticles Coated with a Somatostatin Analogue Target Blood Monocyte for Efficient Leukaemia Treatment;
• 2020 Dec: 177 Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer;
• 2021 Aug: Neuroblastoma xenograft models demonstrate the therapeutic potential of 177 Lu-octreotate;
• 2021 Oct: Targeted paclitaxel-octreotide conjugates inhibited the growth of paclitaxel-resistant human non-small cell lung cancer A549 cells in vitro.

Review

• 1989 Mar: Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors;
• 1990 Mar: The clinical use of somatostatin analogues in the treatment of cancer;
• 1991 Mar: Somatostatin and analogues in the treatment of cancer. A review;
• 1991 Nov: The role of somatostatin and its analogs in the diagnosis and treatment of tumors;
• 1991 Dec: Non-endocrine applications of somatostatin and octreotide acetate: facts and flights of fancy;
• 1992 Sep: Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications;
• 1993 Jan: Growth factor and peptide receptors in small cell lung cancer;
• 1993 Jul-Aug: Use of octreotide acetate for control of symptoms in patients with islet cell tumors;
• 1993 Nov: Somatostatin analogs for diagnosis and treatment of cancer;
• 1994 Jan: Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects;
• 1994 Sep: Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues;
• 1994 Sep: Molecular pharmacology of somatostatin-receptor subtypes;
• 1995 Feb: Neuropeptides in neuroblastomas and ganglioneuromas;
• 1995 May: Neuroendocrine Peptides in the Prostate;
• 1996 Feb: Peptides and growth factors in non-small cell lung cancer;
• 1996 Aug: Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels;
• 1997 Mar: Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action;
• 1997 Sep-Dec: Human somatostatin receptor mediated antiproliferative action evokes subtype selective cytotoxic and cytostatic signaling;
• 1997 Sep-Dec: The potential role of somatostatin analogues in breast cancer treatment;
• 1998 Feb: Mechanisms of antineoplastic action of somatostatin analogs;
• 1998 Jun: Somatostatin receptor expression in multiple endocrine neoplasia and in von Hippel-Lindau disease;
• 1999 Jul: Somatostatin and its receptor family;
• 2000 Feb: New molecular aspects in the diagnosis and therapy of neuroendocrine tumors of the gastroenteropancreatic system;
• 2000 Feb: The significance of somatostatin analogues in the antiproliferative treatment of carcinomas;
• 2000 Feb: Treatment of Endocrine Gastroenteropancreatic Tumors with Somatostatin Analogues;
• 2000 May-Aug: Somatostatin receptors in gliomas;
• 2000 Oct: Peptide analogs in the therapy of prostate cancer;
• 2000 Oct: Somatostatin receptors in the haematopoietic system;
• 2001 Feb: Antiproliferative effect of somatostatin and analogs;
• 2001 Feb: Octreotide in the management of hormone-refractory prostate cancer;
• 2001 Feb: Somatostatin analogs for cancer treatment and diagnosis: an overview;
• 2001 Feb: Somatostatin receptor subtype expression in human tumors;
• 2001 Feb: The somatomedin hypothesis: 2001;
• 2001 Jun: Cancer and the potential place for growth hormone receptor antagonist therapy;
• 2002 Apr: Somatostatins and their role in thyroid cancer;
• 2003 Mar: Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?;
• 2003 Aug: Peptide receptors as molecular targets for cancer diagnosis and therapy;
• 2004 Apr: Molecular signaling of somatostatin receptors;
• 2004 Apr: Phosphotyrosine phosphatase SHP-1, somatostatin and prostate cancer;
• 2004 Apr: Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis;
• 2004 Jun: Regulation and function of somatostatin receptors;
• 2004 Nov: Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma;
• 2004 Dec: Novel modalities of somatostatin actions;
• 2006 Jan-Feb: Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs;
• 2006 Jul: Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach;
• 2006 Dec: Osteosarcoma and acromegaly: a case report and review of the literature;
• 2006 Dec: Rationale for the use of somatostatin analogs as antitumor agents;
• 2007 Jan: Intracranial Meningioma;
• 2007 Apr: Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours;
• 2007 Jun: Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues;
• 2007 Dec: New treatment approaches for prostate cancer based on peptide analogues;
• 2008 Jan: Rational design of competitive prolactin/growth hormone receptor antagonists;
• 2008 Apr: Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors;
• 2008 May: Antitumor effects of somatostatin;
• 2008 May: Biology of somatostatin in breast cancer;
• 2008 May: Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field;
• 2008 May: Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas;
• 2008 May: Somatostatin, cortistatin and their receptors in tumours;
• 2008 May: Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases;
• 2008 May: Targeting growth factors in lung cancer;
• 2009 Feb: Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC);
• 2009 May: Advances in meningioma therapy;
• 2009 Jun: Lanreotide for the treatment of acromegaly;
• 2009 Jun: Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome;
• 2009 Jun: Somatostatin-dopamine ligands in the treatment of pituitary adenomas;
• 2009 Sep: Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology;
• 2009 Nov: Octreotide LAR: safety and tolerability issues;
• 2009 Dec: From somatostatin to octreotide LAR: evolution of a somatostatin analogue;
• 2009 Dec: Nutrition and orthomolecular supplementation in lung cancer patients;
• 2010 Mar: Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review;
• 2010 Mar: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives;
• 2010 Jul: Palliative surgery versus medical management for bowel obstruction in ovarian cancer;
• 2010 Aug: Homing peptides as targeted delivery vehicles;
• 2011 Jan: Somatostatin receptor-targeted anti-cancer therapy;
• 2011 Feb: Somatostatin (SS), SS receptors and SS analog treatment in tumorigenesis;
• 2011 Mar: Malignant bowel obstruction: individualized treatment near the end of life;
• 2011 Jun: Characterization of the differential efficacy of somatostatin receptor agonists in the inhibition of the growth of experimental gliomas and identification of the intracellular mechanisms involved;
• 2011 Jul: Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors;
• 2011 Jul-Aug: Somatostatin in breast cancer [Article in French];
• 2011 Dec: Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics;
• 2012 Jan: Molecular mechanisms of somatostatin receptor trafficking;
• 2012 May: Antitumor effects of somatostatin analogs in neuroendocrine tumors;
• 2012 Jun: The use of therapeutic peptides to target and to kill cancer cells;
• 2012 Aug: Dexamethasone plus somatostatin-analog manipulation as bone metastasis microenvironment-targeting therapy for the treatment of castration-resistant prostate cancer: a meta-analysis of uncontrolled studies;
• 2012 Aug: New agonist- and antagonist-based treatment approaches for advanced prostate cancer;
• 2012 Sep: Octreotide for malignant bowel obstruction: twenty years after;
• 2012 Nov: Neuroendocrine tumors of larynx--two case reports and literature review;
• 2012 Dec: Cancer treatment using peptides: current therapies and future prospects;
• 2013 Jan: Peptide receptor targeting in cancer: the somatostatin paradigm;
• 2013 Jan-Mar: Somatostatin and prostate cancer: role of somatostatin receptors in the control of tumor growth;
• 2013 Apr: A review of the use of somatostatin analogs in oncology;
• 2013 May: Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression;
• 2013 Jun: Somatostatin and Epidermal Growth Factor Receptors: Implications in Breast Cancer;
• 2013 Aug: Somatostatin receptors: from signaling to clinical practice;
• 2013 Dec: Neuroendocrine breast cancer: retrospective analysis of 96 patients and review of literature;
• 2014 Feb: Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives;
• 2014 Mar: Somatostatin analogs: does pharmacology impact antitumor efficacy?;
• 2014 Jun: Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin;
• 2014 Dec: Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations;
• 2015 Jan: GEP-NETs update: Biotherapy for neuroendocrine tumours;
• 2015 May: The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors;
• 2015 Jun: New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones;
• 2015 Jul: Mitochondrial targeted peptides for cancer therapy;
• 2015 Aug: Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs;
• 2015 Aug: Therapeutic uses of somatostatin and its analogues: Current view and potential applications;
• 2015 Nov-Dec: Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis;
• 2016 Jun: From amino acid sequence to bioactivity: The biomedical potential of antitumor peptides;
• 2016 Sep: Breast cancer imaging using radiolabelled somatostatin analogues;
• 2016 Dec: Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors;
• 2017 Jan: Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan;
• 2017 Jan: Review: Receptor Targeted Nuclear Imaging of Breast Cancer;
• 2017 Mar: Evaluation of the use of therapeutic peptides for cancer treatment;
• 2017 Jun: Low Grade Neuroendocrine Tumors of the Lung;
• 2017 Jul: Peptide-Based Cancer-Targeted DDS and Molecular Imaging;
• 2017 Sep: Seek & Destroy, use of targeting peptides for cancer detection and drug delivery;
• 2017 Nov: The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors;
• 2018 Apr: High-grade Non-small Cell Neuroendocrine Carcinoma of the Esophagus;
• 2018 May: Neuroendocrine Factors and Head and Neck Squamous Cell Carcinoma: An Affair to Remember;
• 2018 Jun: Advanced typical and atypical carcinoid tumours of the lung: management recommendations;
• 2018 Jul: Cancer-targeted delivery systems based on peptides;
• 2018 Sep: The over-expression of GH/GHR in tumour tissues with respect to healthy ones confirms its oncogenic role and the consequent oncosuppressor role of its physiological inhibitor, somatostatin: a review of the literature;
• 2018 Oct: International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature;
• 2019 Feb: Tumor targeting peptides: novel therapeutic strategies in glioblastoma;
• 2019 May: Somatostatin and the "Small-For-Size" Liver;
• 2019 Jul: Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives;
• 2019 Sep: Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature;
• 2020 Feb: Somatostatin Analogs in Clinical Practice: a Review;
• 2020 Jul: Laryngeal Neuroendocrine Tumor With Elevated Serum Calcitonin: A Diagnostic and Therapeutic Challenge. Case Report and Review of Literature;
• 2020 Aug: Application of radiolabeled peptides in tumor imaging and therapy;
• 2020 Sep: Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy;
• 2020 Sep: Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives (from Di Bella's Foundation);
• 2020 Oct: Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy;
• 2020 Oct: Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer;
• 2021 Aug: Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview;
• 2021 Oct: Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy;
• 2022 Apr: Neuroendocrine Neoplasms of the Gynecologic Tract;
• 2022 May: Peptide Receptor Radionuclide Therapy in Thyroid Cancer;
• 2022 Jul: Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review;
• 2022 Aug: Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma;
• 2022 Sep: A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer.

Commenti - Editoriali - Lettere all'editore - Corrispondenza

• 1987 Aug: Potential role of somatostatin analogues in the treatment of cancer;
• 1989 Nov: Paralytic ileus responding to somatostatin therapy: first manifestation of a VIPoma;
• 1991 Mar: Somatostatin and the treatment of cancer;
• 1993 Dec: Treatment of advanced pancreatic cancer with high-dose octreotide;
• 1994 Mar: Phase I study of the somatostatin analogue somatuline in refractory small-cell lung carcinoma;
• 1996 Apr: Beneficial effects of octreotide in a patient with a metastatic paraganglioma;
• 2000 Apr: Neurobiology. Receptors as kissing cousins;
• 2000 Oct: Editorial: somatostatin receptor-based scintigraphy and antitumor treatment--an expanding vista?;
• 2004 Aug: Somatostatin and cancer: applying endocrinology to oncology;
• 2007 Jun: Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment;
• 2007 Oct: New Treatment Strategies in the Management of Hormone Refractory Prostate Cancer (HRPC): Only Chemotherapy?;
• 2007 Dec: Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues (Bamias A and Dimopoulos MA);
• 2007 Dec: Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues (McLeod);
• 2008 Apr: Octreotide in palliative treatment of unresectable Cholangiocarcinoma: is it effective for disease stabilization?;
• 2008 May: Octreotide in Palliative Treatment of Hepatic Metastases: Is it Effective for Clinical Stabilization?;
• 2009 Nov: Somatostatin analogs and hepatocellular carcinoma: Not dead yet?;
• 2010 Jun: Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors;
• 2010 Sep: Functional imaging to differentiate pulmonary carcinoids;
• 2012 Jul-Sep: Expression of somatostatin receptors may guide the use of somatostatin receptor imaging and therapy in differentiated thyroid cancer;
• 2014 Oct: Lanreotide in metastatic enteropancreatic neuroendocrine tumors;
• 2014 Oct: Neuroendocrine cancer: CLARINET: new option for NETS;
• 2020 Jul: Editorial Note for Translational Oncology.

Meta-analisi

• 2001 Apr: Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis;
• 2008 Jul: Growth hormone inhibitors in prostate cancer: a systematic analysis;
• 2012 May: Meta-analysis on the effects of octreotide on tumor mass in acromegaly;
• 2012 Aug: Dexamethasone plus somatostatin-analog manipulation as bone metastasis microenvironment-targeting therapy for the treatment of castration-resistant prostate cancer: a meta-analysis of uncontrolled studies;
• 2014 Mar: Thymic Malignancies in the Targeted Therapies Era.

In Vivo (Su uomo: Case Reports/Series, Clinical Trials, Studi comparativi, Prove controllate, randomizzate e Studi retrospettivi)

• 1974 Nov: Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone;
• 1976 Apr: Osteosarcoma associated with acromegaly: a case report;
• 1978 Apr: Somatostatin Inhibits the Pentagastrin-Induced Release of Serum Calcitonin in Medullary Carcinoma of the Thyroid;
• 1985 Jun: The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients;
• 1986 Jul: A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs;
• 1987 Oct: SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years;
• 1988 Feb: Ectopic growth hormone-releasing hormone (GHRH) syndrome in a case with multiple endocrine neoplasia type I;
• 1988 Dec: Effect of a somatostatin analog (SMS 201-995) in perfusion on basal and pentagastrin-stimulated calcitonin levels in medullary thyroid carcinoma;
• 1988 Dec: Successful treatment of unstable angina in malignant carcinoid syndrome using the long-acting somatostatin analogue SMS 201-995 (Sandostatin);
• 1989 Mar: Somatostatin in medullary thyroid cancer. In vitro and in vivo studies;
• 1989 Nov: Paralytic ileus responding to somatostatin therapy: first manifestation of a VIPoma;
• 1989 Dec: Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer;
• 1990 Aug: Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide;
• 1991 Feb: In vitro and in vivo detection of somatostatin receptors in human malignant tissues;
• 1991 Jun: Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma;
• 1991 Jun: The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer;
• 1992 Jan: Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer;
• 1992 Sep: Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial;
• 1992 Nov: Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients;
• 1992 Nov: Somatostatin receptors in human renal cell carcinomas;
• 1993 Dec: Treatment of advanced pancreatic cancer with high-dose octreotide;
• 1993 Feb: Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide;
• 1993 Jun: In vivo somatostatin receptor imaging in medullary thyroid carcinoma;
• 1993 Oct: In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue;
• 1994 Jan: Somatostatin receptor expression in lung cancer;
• 1994 Mar: Phase I study of the somatostatin analogue somatuline in refractory small-cell lung carcinoma;
• 1994 Mar: Somatostatin-receptor scintigraphy in primary breast cancer;
• 1994 May: Somatostatin-receptor imaging of medullary thyroid carcinoma;
• 1995 Jan: Somatostatin receptor imaging in persistent medullary thyroid carcinoma;
• 1995 Feb: Somatostatin and vasoactive intestinal peptide (VIP) in neuroblastoma and ganglioneuroma: chromatographic characterisation and release during surgery;
• 1995 May: Acromegaly and large cell lymphoma;
• 1995 May: Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer;
• 1995 May: Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma;
• 1995 Jan: A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy;
• 1995 Dec: Metastatic Hormone-Refractory Prostatic Adenocarcinoma Expresses Somatostatin Receptors and Is Visualized in Vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide Scintigraphy;
• 1996 Mar: Somatostatin receptor scintigraphy and therapy of neuroendocrine (APUD) tumors of the head and neck;
• 1996 Apr: Beneficial effects of octreotide in a patient with a metastatic paraganglioma;
• 1996 Apr: Dynamic indium-111-pentetreotide scintigraphy in breast cancer;
• 1996 Jun: Octreotide in the management of bowel obstruction in terminal ovarian cancer;
• 1996 Sep: Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide;
• 1997 Feb: Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation?;
• 1997 Oct: Somatostatin in neuroblastoma and ganglioneuroma;
• 1997 Dec: Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors;
• 1998 Feb: Somatostatin receptor expression in Hürthle cell cancer of the thyroid;
• 1998 Mar: Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study;
• 1998 Jun: Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours;
• 1999 Mar: Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report;
• 1999 Oct: Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma;
• 1999 Dec: A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma;
• 2000 Feb: Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue;
• 2000 Feb: The role of radioactive somatostatin and its analogues in the control of tumor growth;
• 2000 Mar: Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma;
• 2000 Apr: Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro;
• 2000 May: Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography;
• 2000 May: Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR;
• 2000 Jun: Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo;
• 2000 Sep: Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide;
• 2000 Nov: Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly;
• 2001 Jan: Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients;
• 2001 Jan: Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide;
• 2001 Mar: Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: more extended disease identified;
• 2001 Apr: Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's lymphomas at advanced stage: results of a phase II trial;
• 2001 May: Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients;
• 2001 Dec: A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients;
• 2002 Jan: Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma;
• 2002 May: Somatostatin Therapy for Glomus Tumors: A Report of Two Cases;
• 2003 Mar: Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group;
• 2003 Apr: Expression of somatostatin receptors in uveal melanomas;
• 2003 Apr: Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage;
• 2003 Aug: Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse;
• 2003 Oct: Case report: patient with multiple paragangliomas treated with long acting somatostatin analogue;
• 2003 Nov: Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer;
• 2004 Jan: Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study;
• 2004 Mar: Oestrogen-mediated Regulation of Somatostatin Receptor Expression in Human Breast Cancer Cell Lines Assessed With 99mTc-depreotide;
• 2004 Apr: Octreotide: an active agent in epithelial ovarian carcinoma?;
• 2004 Jun: One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel;
• 2004 Jul: Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases;
• 2004 Oct: Aggressive pharmacological treatment for reversing malignant bowel obstruction;
• 2004 Dec: Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer;
• 2005 Apr: Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide;
• 2005 Jul: Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone;
• 2005 Dec: Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer;
• 2006 Feb: Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;
• 2006 Feb: Successful treatment of insulinoma by a single daily dose of octreotide in two elderly female patients;
• 2006 Mar: Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2;
• 2006 Mar: Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma;
• 2006 Sep-Oct: Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer;
• 2006 Nov-Dec: Relapse of high-grade non-Hodgkin's lymphoma after autologous stem cell transplantation: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, melatonin, retinoids, and ACTH;
• 2006 Dec: Osteosarcoma and acromegaly: a case report and review of the literature;
• 2007 Jan: Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer;
• 2007 Jan: Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas;
• 2007 Jan-Feb: Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin;
• 2007 Feb: Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;
• 2007 Jun: Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment;
• 2007 Jun: Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial;
• 2007 Aug: Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa;
• 2007 Sep: Recurrent meningioma: salvage therapy with long-acting somatostatin analogue;
• 2007 Nov: Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide;
• 2008 Feb: Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors;
• 2008 Mar: Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: magnetic resonance imaging with 1H-spectroscopy;
• 2008 Mar: Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR;
• 2008 May: Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction;
• 2008 May: Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients;
• 2008 May: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival;
• 2008 Jul: Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly;
• 2008 Nov: Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly;
• 2008 Dec: Complete objective response to biological therapy of plurifocal breast carcinoma;
• 2009 Jan: Octreotide uptake in intracranial metastasis of pancreatic ductal adenocarcinoma origin in a patient with a prolonged clinical course;
• 2009 Feb: Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone;
• 2009 Apr: Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas;
• 2009 Apr-May: Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics;
• 2009 May: [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial;
• 2009 May-Aug: A patient with medullary thyroid carcinoma and right ventricular cardiac metastasis treated by (90)Y-Dotatoc;
• 2009 Jun: Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH;
• 2009 Jun: Radiological imaging change in a malignant bowel obstruction patient treated with octreotide;
• 2009 Aug: Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy;
• 2009 Aug: Somatostatin receptor scintigraphy for optic nerve sheath meningiomas;
• 2009 Sep: Complete objective response of oesophageal squamocellular carcinoma to biological treatment;
• 2009 Sep: Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma;
• 2009 Oct: Complete objective response of neuroblastoma to biological treatment;
• 2009 Nov: Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study;
• 2009 Nov: Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multi-center French study;
• 2009 Dec: A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors;
• 2009 Dec: Efficacy of long-term lanreotide treatment in patients with acromegaly;
• 2009 Dec: Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog;
• 2010 Jan: Eight-year follow-up of a child with a GH-prolactin-secreting adenoma: efficacy of pegvisomant therapy;
• 2010 Jan-Feb: Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT;
• 2010 Feb: Effectiveness of octreotide in advanced cancer patients with malignant bowel obstruction and intractable diarrhea;
• 2010 Mar: Response of recurrent high-grade glioma to treatment with (90)Y-DOTATOC;
• 2010 Mar: Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases;
• 2010 May: Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide;
• 2010 May: The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response;
• 2010 Jul: Octreotide acetate enables the administration of chemoradiotherapy, including the oral anticancer drug S-1, in gastric cancer patients with malignant gastrointestinal obstruction;
• 2010 Aug: Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction;
• 2010 Oct: Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors;
• 2010 Oct: Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study;
• 2010 Dec: Management of androgen-ablation refractory prostate cancer. Role for somatostatin analogues?;
• 2011 Jan: Prevention of breast cancer: the case for studying inhibition of IGF-1 actions;
• 2011 Mar: Can malignant bowel obstruction in advanced cancer patients be treated at home?;
• 2011 Mar: Small cell lung cancer in an elderly patient: efficacy of somatostatin analog treatment, a case report;
• 2011 May: Treatment of unresectable skull base meningiomas with somatostatin analogs;
• 2011 Jun: Inhibitory effect of somatostatin analogue octreotide on the expression of p53 and Ras in human gastric cancer [Article in Chinese: Only the captions of images and tables are in English language];
• 2011 Jun: Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers;
• 2011 Jul: 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma;
• 2011 Jul-Aug: A randomized trial of somatostatin to regulate the VEGFs/VEGFRs in patients with gastric cancer;
• 2011 Sep: The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;
• 2011 Oct: Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ¹¹¹Indium-octreotide imaging;
• 2012 Jan: Post-TACE combination therapy of heparin and octreotide results in decreased tumor metastasis in extrahepatic tumorigenesis;
• 2012 May: Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide;
• 2012 May: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL);
• 2012 May: The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;
• 2012 Jun: Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma;
• 2012 Jun: Ectopic growth hormone-releasing hormone secretion by a bronchial carcinoid tumor: clinical experience following tumor resection and long-acting octreotide therapy;
• 2012 Jul-Aug: Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study;
• 2012 Aug: Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience;
• 2012 Sep: Long-term disease control of a non-operable neuroendocrine tumor of the lung with lanreotide: a case study;
• 2012 Oct: Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer With Neuroendocrine Differentiation;
• 2012 Nov: Neuroendocrine tumors of larynx--two case reports and literature review;
• 2012 Dec: The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 55 cases of lymphomas;
• 2013 May: Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog;
• 2013 May-Jun: The case of a patient affected by primary gliosarcoma and neuroendocrine pancreatic cancer with prolonged survival;
• 2013 Jul: Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies;
• 2013 Aug: Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin;
• 2013 Sep: Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment;
• 2013 Nov: The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature;
• 2013 Dec: Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes;
• 2013 Dec: Effects of octreotide therapy in progressive head and neck paragangliomas: case series;
• 2013 Dec: Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;
• 2013 Dec: Neuroendocrine breast cancer: retrospective analysis of 96 patients and review of literature;
• 2013 Dec: Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis;
• 2014 Jan: The use of lanreotide autogel® in the treatment of intestinal obstruction in a patient with adenocarcinoma;
• 2014 Mar: High-dose lanreotide in the treatment of poorly differentiated pancreatic neuroendocrine carcinoma: a case report;
• 2014 Apr: Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients;
• 2014 Apr: Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced "in Vivo" by 68Ga-DOTANOC PET/CT: Two Cases;
• 2014 Apr: Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging;
• 2014 Jun: Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours;
• 2014 Jun: Merckel cell carcinoma of the skin treated with somatostatin analogue and mTOR inhibitor exhausted after primary surgery, adjuvant radiotherapy and palliative chemotherapy;
• 2014 Jul: Lanreotide in metastatic enteropancreatic neuroendocrine tumors;
• 2014 Aug: Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas;
• 2014 Sep: Long-term disease control of a pancreatic neuroendocrine tumor with lanreotide autogel(®): a case report;
• 2014 Oct: Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma;
• 2014 Oct: Effect of somatostatin in advanced gastric cancer after D2 radical gastrectomy;
• 2014 Nov: Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial;
• 2015 Feb: Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors;
• 2015 Feb: mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer;
• 2015 Feb: Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer;
• 2015 May: Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;
• 2015 May: Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two cases;
• 2015 Jun: Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT: preliminary report of in six patients;
• 2015 Jul: Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis;
• 2015 Oct: Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids;
• 2015 Nov: Neuroendocrine differentiation in castration-resistant prostate cancer: A case report;
• 2016 Jan: Congenital fibrosarcoma in complete remission with Somatostatin, Bromocriptine, Retinoids, Vitamin D3, Vitamin E, Vitamin C, Melatonin, Calcium, Chondroitin sulfate associated with low doses of Cyclophosphamide in a 14-year Follow Up. Case Report;
• 2016 Jan: Somatostatin analogs in the treatment of castrate-resistant prostate cancer: efficacy and tolerability;
• 2016 Jan-Apr: Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE;
• 2016 Jan-Apr: Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case;
• 2016 Feb: Efficacy of octreotide against chylothorax following lateral neck dissection for thyroid cancer: A case report;
• 2016 Feb: Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy;
• 2016 Mar: Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study;
• 2016 May: EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL;
• 2016 Jun: Effect of Octreotide Injection on Postoperative Drainage After Neck Dissection: A Preliminary Report of a Prospective, Matched Case-Control Study;
• 2016 Jul: 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors;
• 2016 Aug: Unresectable Recurrent Multiple Meningioma: A Case Report with Radiological Response to Somatostatin Analogues;
• 2016 Nov: Does combination of "cold" and "hot" somatostatin analogs prolong survival of patients with neuroendocrine neoplasms?;
• 2016 Nov: Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: A case report;
• 2016 Nov: Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours;
• 2017 Jan: Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report;
• 2017 Apr: Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids;
• 2017 May: Association between osteosarcoma and acromegaly: a new case report;
• 2017 May: SPECT-CT Somatostatin-Receptor Scintigraphy in Medullary Thyroid Cancer (MTC);
• 2017 Jul-Sep: Glomus Tumor of the Larynx: A Rare Synchronous Paraganglioma in a Patient with Bilateral Carotid Body Tumor Detected on 68Ga-DOTANOC PET/CT;
• 2017 Sep: Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma;
• 2017 Sep-Dec: Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report;
• 2017 Nov: Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues;
• 2017 Nov: Somatostatin receptors expression in breast cancer;
• 2017 Dec: Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast.
• 2017 Dec: Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial;
• 2018 Feb: Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer;
• 2018 Feb: Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms;
• 2018 Jan: 111In-DTPA-Octreotide SPECT (OctreoScan) Uptake in Metastatic Renal Cell Carcinoma to the Pancreas;
• 2018 Mar: Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis;
• 2018 Mar: Somatostatin Receptor Expression in Renal Cell Carcinoma-A New Front in the Diagnostics and Treatment of Renal Cell Carcinoma;
• 2018 Mar: The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study;
• 2018 Mar: The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer;
• 2018 Apr: A Rare Case of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (Anampa-Guzman & Raez);
• 2018 Apr: High-grade Non-small Cell Neuroendocrine Carcinoma of the Esophagus;
• 2018 Apr: Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour;
• 2018 Jun: Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer;
• 2018 Jul: Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma;
• 2018 Sep: Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: A case report;
• 2018 Oct: Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN);
• 2018 Oct: Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A;
• 2018 Nov: A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib;
• 2018 Nov: Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer;
• 2018 Dec: A case of malignant insulinoma responsive to somatostatin analogs treatment;
• 2019 Mar: A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial;
• 2019 Aug: Duodenal neuroendocrine tumour associated with minimal change glomerulonephritis;
• 2019 Oct-Dec: 177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment;
• 2019 Dec: Renal Neuroendocrine Neoplasms: A Single-center Experience;
• 2020 Jan: Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma;
• 2020 Mar: Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist;
• 2020 Apr: High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma;
• 2020 May: A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas;
• 2020 Jun: Investigation of somatostatin receptor profile of neuroendocrine carcinomas of the breast;
• 2020 Jul: Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours;
• 2020 Jul: Laryngeal Neuroendocrine Tumor With Elevated Serum Calcitonin: A Diagnostic and Therapeutic Challenge. Case Report and Review of Literature;
• 2020 Jul: Somatostatin Receptors in Merkel-Cell Carcinoma: A Therapeutic Opportunity Using Somatostatin Analog Alone or in Association With Checkpoint Inhibitors Immunotherapy. A Case Report;
• 2020 Aug: Repeat hepatectomy for liver metastases from bile duct neuroendocrine tumor: a case report;
• 2020 Sep-Dec: First Case of Regression of Carcinoid Heart Disease on Serial Transthoracic Echocardiograms following Octreotide Monotherapy in a Patient with Metastatic Pancreatic Neuroendocrine Tumor;
• 2020 Dec: 177 Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer;
• 2020 Dec: 68 Ga DOTANOC PET/CT Scan in Primary Juvenile Nasopharyngeal Angiofibroma - A Pilot Study;
• 2021 Jan-Apr: Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer;
• 2021 Feb: Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series;
• 2021 Jun: Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials;
• 2021 Nov: A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness (from Di Bella's Foundation);
• 2022 Jan: Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis;
• 2022 Feb: Evaluating Use of the Octreotide Acetate Pen Injector in a Summative Human Factors Validation Study;
• 2022 May: A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer;
• 2022 Jun: A Retrospective Observational Study on Cases of Sarcoma Treated with the Di Bella Method: Rationale and Effectiveness (from Di Bella's Foundation)
• 2022 Sep: A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness (from Di Bella's Foundation).